<DOC>
	<DOCNO>NCT02583893</DOCNO>
	<brief_summary>This pilot phase II trial study whether biomarkers ( biological molecule ) bone marrow sample predict treatment response sirolimus chemotherapy ( mitoxantrone hydrochloride , etoposide , cytarabine [ MEC ] ) patient acute myeloid leukemia ( AML ) likely come back spread ( high-risk ) . Sirolimus inhibit block pathway cause cancer cell grow . Adding sirolimus standard chemotherapy may help improve patient response . Studying sample bone marrow patient treat sirolimus laboratory may help doctor learn whether sirolimus revers turn pathway whether change biomarker level predict well patient respond treatment .</brief_summary>
	<brief_title>Biomarkers Predicting Treatment Response Sirolimus Chemotherapy Patients With High-Risk Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To test association biochemical response clinical response . SECONDARY OBJECTIVES : I . To estimate complete response rate sirolimus MEC patient high risk AML . II . To estimate progression free survival patient population . III . To collect information safety , tolerability , efficacy sirolimus combination MEC patient relapse refractory myeloid malignancy . OUTLINE : Patients undergo collection bone marrow sample prior sirolimus dose day 4 within 1 week later day 45 hematologic recovery . Patients receive sirolimus orally ( PO ) day 2-9 ( load dose day 1 ) , standard MEC chemotherapy comprise mitoxantrone hydrochloride intravenously ( IV ) 15 minute , etoposide IV 1 hour , cytarabine IV 1 hour every 24 hour day 4-8 . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Patients must histologic evidence high risk acute myeloid leukemia define one following : 1 . Primary refractory nonM3 AML Residual leukemia minimum 2 prior course chemotherapy ( Same different ) Evidence leukemia recurrence nadir bone marrow biopsy demonstrate evidence residual leukemia . Evidence leukemia induction therapy , opinion investigator , would appropriate reinduction sirolimus/MEC therapy . 2 . Relapsed nonM3 AML 3 . Previously untreated nonM3 AML age &gt; 60 evidence favorable karyotype define presence ( 8 ; 21 ) ( q22 ; q22 ) [ AML1ETO ] , inv16 ( p13 ; q22 ) , ( 16 ; 16 ) ( p13 ; q22 ) [ CBFβ ; MYH11 ] cytogenetics , FISH , RTPCR 4 . Previously untreated secondary AML ( antecedent hematologic malignancy follow therapy radiation chemotherapy another disease ) evidence favorable karyotype define presence ( 8 ; 21 ) ( q22 ; q22 ) [ AML1ETO ] , inv16 ( p13 ; q22 ) , ( 16 ; 16 ) ( p13 ; q22 ) [ CBFβ ; MYH11 ] cytogenetics , FISH , RTPCR 2 . Subjects must ≥ 18 year age . 3 . Subjects must ECOG performance status 2 le ( see Appendix1 ) . 4 . Subjects must life expectancy least 4 week . 5 . Subjects must able consume oral medication . 6 . Subjects must recover toxic effect prior chemotherapy &lt; Grade 1 ( except alopecia ) . 7 . Required initial laboratory value : 1 . Creatinine ≤ 2.0mg/dL 2. total direct bilirubin ≤ 1.5mg/dL ; SGPT ( ALT ) ≤ 3xULN 3. negative pregnancy test woman childbearing potential . 8 . Patients must able sign consent willing able comply schedule visit , treatment plan laboratory testing . 9 . Subjects must leave ventricular ejection fraction ( LVEF ) ≥ 45 % . 1 . Subjects FAB M3 ( ( 15 ; 17 ) ( q22 ; q21 ) [ PMLRARα ] ) eligible . 2 . Subjects must receive chemotherapy agent ( except Hydroxyurea ) . ) Intrathecal methotrexate cytarabine permissible . 3 . Subjects must receive growth factor , except erythropoietin . 4 . Subjects `` currently active '' second malignancy , nonmelanoma skin cancer eligible . 5 . Subjects uncontrolled high blood pressure , unstable angina , symptomatic congestive heart failure , myocardial infarction within past 6 month serious uncontrolled cardiac arrhythmia eligible . 6 . Subjects take follow eligible : 1 . Carbamazepine ( e.g. , Tegretol ) 2 . Rifabutin ( e.g. , Mycobutin ) 3 . Rifampin ( e.g. , Rifadin ) 4 . Rifapentine ( e.g. , Priftin ) 5 . St. John 's wort 6 . Clarithromycin ( e.g. , Biaxin ) 7 . Cyclosporine ( e.g . Neoral Sandimmune ) 8 . Diltiazem ( e.g. , Cardizem ) 9 . Erythromycin ( e.g. , AkneMycin , EryTab ) 10 . Itraconazole ( e.g. , Sporanox ) 11 . Ketoconazole ( e.g. , Nizoral ) 12 . Telithromycin ( e.g. , Ketek ) 13 . Verapamil ( e.g. , Calan SR , Isoptin , Verelan ) 14 . Voriconazole ( e.g. , VFEND ) 15 . Tacrolimus ( e.g . Prograf ) Subjects take fluconozole , voriconizole , itraconazole , posaconazole , ketokonazole within 72 hour study drug start eligible . Reinstitution fluconozole , voriconizole , itraconazole , posaconazole , ketokonazole diltiazem permissible 72 hour last dose sirolimus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>